Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05625724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

Study acronym: APPART
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: May 2025 to Aug 2028 Completion date: May 2026 to May 2029v4 Show 1 more changeShow less
    • Completion date: May 2026 to May 2029
  2. Study sites: 22 to 21v3
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 2023 to Aug 2, 2023 · Site details revised at 22 of 22 sites · Study description expanded, about 2 wordsv2 Show 3 more changesShow less
    • Start date changed from estimate of May 2023 to Aug 2, 2023
    • Site details revised at 22 of 22 sites
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.
Trial Details
NCT Number NCT05625724
Lead Sponsor University Hospital, Toulouse
Conditions ART, Pre-Eclampsia
Enrollment 1,164 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov